The Oral Microbiome in OSCC

Sponsor
University of Iowa (Other)
Overall Status
Recruiting
CT.gov ID
NCT04925700
Collaborator
(none)
24
1
2
15.4
1.6

Study Details

Study Description

Brief Summary

Previous work by a number of scientific teams has revealed that the types of bacteria that colonize the mouth differ between health and pre-cancerous or cancerous oral lesions. The purpose of this study is to investigate the extent of these changes and to correlate the changes with alterations in the activities of the host's own oral tissues. In doing so, we believe we can gain a better understanding of how particular bacterial species, or consortia of species, can result in an individual having an increased risk of the most common type of oral cancer -- oral squamous cell carcinoma. This knowledge may also lead to the identification of salivary biomarkers that can be used for clinical evaluation or screening. In addition, we seek to determine the extent to which a probiotic regimen can help prevent or rectify the disease-related changes in the types of bacterial colonizing the mouth. The microbiome in health, pre-cancerous lesions, and cancerous lesions will be determined from remnant microbial DNA in banked tissue samples. The effects of probiotics on the oral microbiome will be determined from DNA collected from swabs of oral tissue at baseline and then after 3 to 6 months of probiotic usage.

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: ProDentis Lozenge
  • Other: Placebo Lozenge
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
24 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
The Oral Microbiome in Oral Squamous Cell Carcinoma
Actual Study Start Date :
Apr 20, 2022
Anticipated Primary Completion Date :
Jul 1, 2023
Anticipated Study Completion Date :
Aug 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Probiotic Lozenge

Dietary Supplement: ProDentis Lozenge
1-2 ProDentis Lozenges per day

Placebo Comparator: Placebo Lozenge

Other: Placebo Lozenge
1-2 Placebo Lozenges per day

Outcome Measures

Primary Outcome Measures

  1. Assessment of changes in the oral microbiome composition over time [Up to 3 months]

    16S Genomic Profiling will be done in all recruited subjects via oral swab of pre-cancerous or cancerous oral lesion

  2. Determine the Effect of ProDentis on the Oral Microbiome [Up to 3 months]

    Pre-Cancerous lesion is treatment planned as "watch-and-wait" or oral lesion is not present, recruited subjects will be randomly assigned to either the probiotic lozenge or placebo lozenge group.

Eligibility Criteria

Criteria

Ages Eligible for Study:
21 Years to 89 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Adults (21-70 years old) who have been diagnosed with oral dysplasia or that have been treatment-planned as wait and watch or

  2. Adults (21-70 years old) or who have been diagnosed with oral squamous cell carcinoma, or matched healthy controls free of any oral lesions

Exclusion Criteria:
  1. Adults who have had a course of antibiotics that was completed less than 3 months prior to the study;

  2. Adults with any immunosuppressive condition or medication that would put the subject at risk of consuming daily probiotics;

  3. Adults who regularly use probiotic dietary supplements

  4. Adults that have alcohol/tobacco use history that does not match study population - this if for the healthy controls arm only.

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Iowa College of Dentistry and Dental Clinics Iowa City Iowa United States 52242

Sponsors and Collaborators

  • University of Iowa

Investigators

  • Principal Investigator: David Drake, MS, PhD, University of Iowa College of Dentistry

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
David R. Drake, Professor, University of Iowa
ClinicalTrials.gov Identifier:
NCT04925700
Other Study ID Numbers:
  • 202012278
First Posted:
Jun 14, 2021
Last Update Posted:
Aug 5, 2022
Last Verified:
Aug 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 5, 2022